REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 174 filers reported holding REATA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $14,682 | +11.4% | 144 | -0.7% | 0.00% | 0.0% |
| Q1 2023 | $13,183 | +339.3% | 145 | +83.5% | 0.00% | – |
| Q4 2022 | $3,001 | +50.0% | 79 | +8.2% | 0.00% | – |
| Q3 2022 | $2,000 | +100.0% | 73 | +49.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 49 | +96.0% | 0.00% | – |
| Q1 2022 | $1,000 | -66.7% | 25 | -3.8% | 0.00% | -100.0% |
| Q3 2021 | $3,000 | -25.0% | 26 | -16.1% | 0.00% | 0.0% |
| Q2 2021 | $4,000 | -20.0% | 31 | -36.7% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -16.7% | 49 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $6,000 | +200.0% | 49 | +145.0% | 0.00% | 0.0% |
| Q3 2020 | $2,000 | -93.8% | 20 | -95.0% | 0.00% | -91.7% |
| Q3 2019 | $32,000 | – | 400 | – | 0.01% | – |
| Q2 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q1 2019 | $42,000 | 0.0% | 500 | -33.3% | 0.02% | -19.0% |
| Q4 2018 | $42,000 | – | 750 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 3,063,567 | $298,453,000 | 49.63% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 150,000 | $14,613,000 | 19.62% |
| Corriente Advisors, LLC | 300,000 | $29,226,000 | 14.82% |
| Prosight Management, LP | 114,554 | $11,160,000 | 5.31% |
| MADDEN SECURITIES Corp | 43,927 | $4,279,000 | 3.18% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $2,958,000 | 2.24% |
| Biondo Investment Advisors, LLC | 99,652 | $9,708,000 | 2.10% |
| Cormorant Asset Management, LP | 450,000 | $43,839,000 | 1.69% |
| Duquesne Family Office | 543,901 | $52,987,000 | 1.54% |
| AWH Capital, L.P. | 9,500 | $925,000 | 1.30% |